DMykG
Deutschsprachige Mykologische Gesellschaft

ÖGMM

60th Scientific Conference of the German speaking Mycological Society (DMykG) e. V.
together with
Austrian Society for Medical Mycology (ÖGMM)



PROGRAMME

Myk2026

17–19 September I Graz

www.dmykg-kongress.de

Gemeinsam die Zukunft der Gesundheitsversorgung gestalten

SHIONOGI



150-jährige Expertise
in der Medikamentenentwicklung

Innovationen gegen Infektionskrankheiten
und andere seltene Erkrankungen mit hohem medizinischem Bedarf

Verbesserung der Patientenversorgung
in Deutschland, Österreich und darüber hinaus

Besuchen Sie unser Lunchsymposium

Invasive Pilzinfektionen im Wandel: Diagnostik und Therapie neu denken

Freitag, 18.09. 2026 | 11:15 Uhr – 12:15 Uhr | Raum: Aula

Vorsitz:

Assoz. Prof. Priv.-Doz. Dr. med. univ. Martin Hönigl
Medizinische Universität Graz

Referent:innen:

- **Univ.-Prof. Dr. rer. nat. Michaela Lackner**
  Medizinische Universität Innsbruck
- **Prof. Dr. med. Tobias Lahmer**
  TUM Klinikum Rechts der Isar
- **Univ.-Prof. Dr. med. Oliver Cornely**
  Universitätsklinikum Köln

Sie finden uns an Stand 3!

Programme overview
- Thursday, 17 September 4
- Friday, 18 September 5
- Saturday, 19 September 6

Organisation and imprint 7

Welcome notes
- by the Conference chairs 8
- by the Presidents of the DMykG and ÖGMM 9

Invited speakers and keynote speakers 12

Scientific programme
- Thursday, 17 September 14
- Friday, 18 September 18
- Saturday, 19 September 22

Poster sessions
- Thursday, 17 September 28
- Friday, 18 September 31

General information 36

Social programme 40

Sponsors, exhibitors and industrial symposia
- Sponsors and exhibitors 42
- Grants 43
- Media cooperations 43
- Industrial symposia 44
- Floor and exhibition plan 46

Index speakers, authors and chairs 48

OVERVIEW

Aula	Lecture hall 5	Foyer
	10:00–11:30 **ÖGMM General Assembly** p. 14	
12:00–12:15 Opening Ceremony p. 14 **12:15–13:30** Awards Ceremony p. 14		
		13:30–13:45 Break
13:45–14:30 **Keynote lecture 1** p. 14		
		14:30–16:00 Break
14:45–15:45 Industrial Symposium 1 p. 44		
16:00–17:00 **Session 1** Clinical management of acute and chronic fungal diseases p. 14	**16:00–17:00** **Session 2** Fungal virulence and impact of climate change p. 15	
17:00–18:00 **Session 3** Mycobiome and fungal colonization p. 15	**17:00–18:00** **Session 4** Pediatric fungal infections p. 16	
		18:00–18:15 Break
18:15–18:45 **Keynote Lecture 2** p. 17		
18:45–19:15 Ehrenmitgliedschaft ÖGMM & Lesungen p. 17		
	19:15–20:15 Poster Session 1 p. 28	**19:15–21:15** Welcome Reception p. 40

Aula	Lecture hall 5	Foyer	Atelier
08:00–08:45 **Keynote Lecture 3** p. 18			
08:45–09:45 Industrial Symposium 2 p. 45		**08:45–10:00** Break	
10:00–11:00 **Session 5** Novel fungal diagnostics p. 18	**10:00–11:00** **Session 6** Host-fungal pathogen interactions p. 19		
11:15–12:15 Industrial Symposium 3 p. 45		**11:00–13:15** Lunch Break	
12:30–13:15 **Round Table:** The Future of Medical Mycology p. 19			
			13:15–14:15 Poster Session 2 p. 31
14:15–15:15 **Session 7** Rethinking risk: Fungal infections in non-classical hosts p. 20	**14:15–15:15** **Session 8** One Health: Fungicides, Mycotoxins and Resistance p. 20		
15:15–16:00 **Keynote Lecture 4** Candida cell wall architecture impact p. 21			
	16:00–18:00 DMykG General Assembly p. 21		

18:30-19:30
Guided tour of Graz

19:30-23:00
Social evening at Landhauskeller
p. 40

Aula	Lecture hall 5	Foyer
08:30–10:00 Rapid Fire Session p. 22		
		10:00–10:15 Break
10:15–11:15 **Session 9** Precision antifungal therapy: translating pharmacology into better patient outcomes (ÖGIT/ÖGMM) p. 23	**10:15–11:15** **Session 10** Systems biology of fungal infections p. 23	
		11:15–11:30 Break
11:30–12:30 **Session 11** Mucosal fungal interactions p. 24	**11:30–12:30** **Session 12** Dermatomykologie p. 25	
12:30–13:00 Closing		

ÖGMM Meetings
Opening & Closing
Social programme
Keynote lecture
Industrial symposia
Scientific sessions
Poster sessions
Break and visiting the industrial exhibition
Other sessions
DMykG Meetings

Venue
Medizinische Universität Graz
Neue Stiftingtalstraße 6 I 8010 Graz, Austria

Conference homepage
www.dmykg-kongress.de

Scientific organizer
German speaking Mycological Society (DMykG) e.V.

Austrian Society for Medical Mycology (ÖGMM)

Conference chairs
Priv.-Doz. Dr. Dr. Jürgen Prattes
Assoz.-Prof. Priv.-Doz. Dr. Martin Hönigl
Department of Internal Medicine, Division of Infectious Diseases, Medical University of Graz

Scientific committee
Dr. Angelika Bauer (Austria)
Priv. Doz. Mag.rer.nat
Ulrike Binder (Austria)
Assoz.-Prof. Subhra Kumar Biswas (Austria)
Prof. Dr. Axel A. Braghage (Germany)
Prof. Agostinho Carvalho (Portugal)
Dr. Mark Gresnigt (Germany)
Prof. Neil Gow (United Kingdom)
Prof. Dr. Ilse Jacobsen (Germany)
Assoz.-Prof. Priv.-Doz. Dr.
Martin Hönigl (Austria)
Prof. Dr. rer. nat.
Sven Krappmann (Germany)
Univ.-Prof. Dr. Robert Krause (Austria)
Prof. Dr. med. Oliver Kurzai (Germany)
Univ.-Prof. Dr. Michaela Lackner (Austria)
Prof. Dr. med.
Thomas Lehrnbecher (Germany)
Prof. Dr. Jürgen Löffler (Germany)
Prof. Dr. med. Pietro Nenoff (Germany)
Priv.-Doz. Dr. Dr. Jürgen Prattes (Austria)
Mag. Dr. rer. nat. Günter Rambach (Austria)
Dr. Katharina Rosam (Austria)
Univ.-Prof. Dr. Helmut Salzer (Austria)
Assoc. Prof. Priv.-Doz. Dr.
Peter Schellongowski (Austria)
Dr. scient. med. Kathrin Spettel (Austria)

Professional conference organizer
Conventus Congressmanagement & Marketing GmbH
Ms Mara Machill
+49 3641 31 16-344
dmykg-conference@conventus.de I www.conventus.de

Programme creation

Layout	Conventus Congressmanagement & Marketing GmbH
Print	printworld.com GmbH I Messering 5 I 01067 Dresden
Edition	200
Editorial deadline	20 August 2026

WELCOME NOTE BY THE CONFERENCE CHAIRS

Dear Colleagues and Friends,

It is our great pleasure to welcome you to MYK 2026, the 60th Annual Meeting of the German speaking Mycological Society (DMykG), taking place from 17–19 September 2026 at the Medical University of Graz, Austria.

Celebrating this milestone together with the Austrian Society for Medical Mycology (ÖGMM) makes this year's meeting particularly special. Every four years, the DMykG and ÖGMM jointly organize the MYK conference, reflecting the close collaboration and long-standing partnership of the German-speaking medical mycology community. We are delighted to host this year's meeting in Graz.

The scientific program brings together international expertise in clinical mycology, and host-fungal pathogen interactions, as well as other translational and basic research, leveraging from the GALActIC consortium meeting taking place in Graz immediately before the MYK. Highlights include keynote lectures by Prof. Frank van de Veerdonk (Nijmegen, The Netherlands), Assoc.-Prof. Daniele R. Giacobbe (Genova, Italy), Prof. Joost Wauters (Leuven, Belgium), and Prof. Neil Gow (Exeter, United Kingdom), who will provide perspectives on key developments in medical mycology. Another highlight is the joint symposium with the Austrian Society for Infectious Diseases and Tropical Medicine (ÖGIT), emphasizing the close links between medical mycology and infectious diseases.

Beyond the scientific program, we hope you will enjoy the unique atmosphere of Graz – a vibrant university city, UNESCO World Heritage Site, and welcoming meeting place for scientific exchange, collaboration, and friendship.

We sincerely thank all speakers, chairs, members of the Scientific Committee, our supporting societies, industry partners, and the organizing team for their dedication and commitment.

We wish you an inspiring meeting, stimulating discussions, and an enjoyable stay in Graz.

Priv.-Doz. Dr. Dr. Jürgen Prattes
Assoz.-Prof. Priv.-Doz. Dr. Martin Hönigl

Dear Colleagues and Friends,

It is our great pleasure to warmly welcome you to MYK 2026 in Graz, the joint anniversary meeting of the German speaking Mycological Society (DMykG) and the Austrian Society for Medical Mycology (ÖGMM). This 60th MYK marks a special milestone in the close collaboration of our two societies and in the development of medical mycology in the German-speaking countries.

The major challenges in our field—rising numbers of invasive fungal infections, the emergence of new pathogens, and the relentless spread of antifungal resistance—demand coordinated, cross-border and interdisciplinary responses. Our societies aim to create a shared platform where clinicians, microbiologists, infectious disease specialists, pharmacists, epidemiologists, basic scientists, and public health professionals can come together to discuss new findings, align strategies and build durable networks that extend well beyond this meeting.

The scientific program of MYK 2026 in Graz will span the full breadth of contemporary medical mycology: from invasive mould and yeast infections in hematology, oncology, intensive care and transplantation, to innovations in diagnostics, antifungal pharmacotherapy and stewardship, and the design and interpretation of clinical trials. Emphasis will be placed on antifungal resistance, including molecular epidemiology, surveillance initiatives, One Health and the complex interplay between environmental antifungal use and clinical resistance. At the same time, the congress will highlight emerging fungal pathogens, global epidemiological trends and preparedness for future fungal threats, reflecting the growing recognition of fungal diseases as a key component of global health and planetary health.

We are delighted that MYK 2026 is hosted under the local leadership of Assoz.-Prof. Priv.-Doz. Dr. Martin Hönigl and Priv.-Doz. Dr. Dr. Jürgen Prattes, whose team in Graz has long been recognized for its contributions to clinical mycology and invasive fungal infections. Together with the scientific committees of DMykG and ÖGMM, they are assembling a programme that combines cutting-edge basic and translational research with immediately applicable clinical content. State-of-the-art lectures, focused symposia, case-based sessions and abstract-driven oral and poster presentations will ensure that the meeting captures both the breadth and the depth of current mycological research and practice.

A particular focus of MYK 2026 will be on supporting and empowering the next generation of mycologists and infectious disease specialists. We see this as a natural extension of existing training and capacity-building initiatives in our societies and as an essential investment in the future of our field.

WELCOME NOTE BY THE PRESIDENTS OF THE DMYKG AND ÖGMM

Graz itself provides an ideal environment for this joint meeting: a dynamic university city with strong expertise in infectious diseases and clinical microbiology, and a compact setting that encourages both intense scientific exchange and informal encounters.

On behalf of both societies, we warmly invite you to the MYK 2026.

Oliver Kurzai (President DMKYG)
Michaela Lackner (President ÖGMM)



© dhanu3182- stock.adobe.com



GILEAD

RECHTZEITIG HANDELN UND LEBEN RETTEN

BEI INVASIVEN PILZINFEKTIONEN



AmBisome®

Liposomales Amphotericin B 50mg

- **Hohe nachgewiesene Wirksamkeit** bei den meisten klinisch bedeutsamen Hefe- und Schimmelpilzen[3-5]
- **Gute Verträglichkeit** durch liposomale Formulierung[7-10]
- **Zuverlässige Wirkspiegel**[1] ohne therapeutisches Drug Monitoring[2]

1 Walsh TJ et al. Antimicrob Agents Chemother 1998; 42: 2391 – 2398. **2** Mousset S et al. Ann Hematol 2014; 93: 13 – 32. **3** Lass-Flörl C et al. Antimicrob Agents Chemother 2008; 52: 3637 – 3641. **4** Ellis D. J Antimicrob Chemother 2002; 49 (Suppl 1): 7 – 10. **5** Cuenca-Estrella M et al. Antimicrob Agents Chemother 2006; 50(3): 917 – 921. **6** Brodt HR (Hrsg.). Antibiotika-Therapie. Klinik und Praxis der antiinfektiösen Behandlung. 12. Aufl. Schattauer Verlag 2013; 378 – 382. **7** Falci DR et al. Mycoses. 2015;58:104-112. **8** Walsh TJ et al. NEJM 1999;340:764-771. **9** Wingard JR et al. Clin Infect Dis 2000;31:1155-1163. **10** Leenders AC et al. Br J Haematol 1998;103:205-212.

AmBisome Amphotericin B liposomal 50 mg, Pulver zur Herstellung einer Infusionsdispersion

Pharmakotherapeutische Gruppe: Antimykotika zur systemischen Anwendung, Antibiotika; ATC-Code: J02AA01. **Qualitative und quantitative Zusammensetzung:** 1 Durchstechflasche enthält 50 mg Amphotericin B eingebettet in Liposomen. Nach der Rekonstitution enthält das Konzentrat 4 mg/ml Amphotericin B. *Sonstiger Bestandteil mit bekannter Wirkung:* Natrium. **Sonstige Bestandteile:** Hydriertes Sojaphosphatidylcholin, Cholesterol, Distearoylphosphatidylglycerol, Saccharose, Dinatriumsuccinat-Hexahydrat, α-Tocopherol, Natriumhydroxid (zur pH-Einstellung), Salzsäure (zur pH-Einstellung). **Anwendungsgebiete:** AmBisome ist angezeigt zur - Behandlung von schweren systemischen und/oder tiefen Mykosen. Zu den erfolgreich mit AmBisome behandelten Mykosen gehören disseminierte Candidose, Aspergillose, Kryptokokkenmeningitis, Mucormykose und chronisches Myzetom. - empirischen Behandlung von vermuteten Pilzinfektionen bei Patienten mit febriler Neutropenie. AmBisome wird angewendet bei Säuglingen, Kleinkindern, Kindern, Jugendlichen und Erwachsenen. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der Bestandteile, außer wenn nach Meinung des Arztes die zu behandelnde Infektion lebensbedrohlich ist und nur mit AmBisome behandelt werden kann. **Inhaber der Zulassung:** Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Irland. **Rezept- und apothekenpflichtig, NR. Weitere Angaben zu Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen, Schwangerschaft und Stillzeit, sowie Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation.**

AT-AMB-0006

Gilead Sciences GesmbH
Wagramer Straße 19, A-1220 Wien

AT-AMB-0160; Erstellungsdatum: 03/2026

SPEAKERS

Keynote speakers

Ass. Prof. Dr. Daniele Roberto Giacobbe
University of Genoa

Prof. Neil Gow
University of Exeter

Prof. Dr. Frank Van De Veerdonk
Radboud University Medical Center

MD PhD Joost Wauters
KU Leuven

Invited speakers

PD Dr. med. Konrad Bochennek
Frankfurt University Medical Center

Dr. rer. Nat. habil. Matthias Brock
University of Nottingham

Prof. Dr. Roger Brüggemann
Radboud University Medical Center

PhD Agostinho Carvalho
University of Minho

Prof. Dr. Georgios Chamilos
University of Crete - School of Medicine

Prof. Dr. Oliver A. Cornely
University Hospital Cologne

MD PhD Simon Feys
UZ Leuven

Univ.-Prof. Dr. Gabriele Ginter-Hanselmayer
Medical University of Graz

Prof. Dr. Ilse Jacobsen
Leibniz-HKI

Univ.-Prof. Dr. Robert Krause
Medical University of Graz

Prof. Dr. Maja Segvic Klaric
University of Zagreb

Univ.-Prof. Mag. Dr. rer. nat. Michaela Lackner
Innsbruck Medical University

Univ.-Prof. Dr. Cornelia Lass-Flörl
Innsbruck Medical University

Prof. Dr. Virginie Lemiale
Hospital Saint-Louis - AP-HP

Dr. med. Christin Pelzer
HOCH Health Ostschweiz – Cantonal Hospital St. Gallen

Prof. Dr. Helmut Salzer
Kepler University Hospital

Peter Schellongowski
Medical University of Vienna

Prof. Dr. Grit Walther
Leibniz-HKI

PROGRAMME



© christian vinces - stock.adobe.com

10:00–11:30 ÖGMM General Assembly
Room Lecture hall 5

12:00–12:15 Opening Ceremony
Room Aula

12:00 Welcome note by the conference chairs

12:05 Welcome note by the representative of the Medical University of Graz

12:10 Welcome note by the representative of the City of Graz

12:15–13:30 Awards Ceremony
Room Aula

13:45–14:30 Keynote Lecture 1
Room Aula
Chair Martin Hönigl (Graz/AT)

13:45 KL-1
Host directed Management of Invasive Fungal Diseases
Frank van de Veerdonk (Nijmegen/NL)

14:45–15:45 Industrial Symposium 1
see page 44

16:00–17:00 Session 1 • Clinical management of acute and chronic fungal diseases
Room Aula
Chairs Robert Krause (Graz/AT), Rosanne Sprute (Cologne/DE)

16:00 S1-01
New antifungals in clinical development: Who's in and who's out
Oliver A. Cornely (Cologne/DE)

16:20 S1-02
Focus on chronic fungal infections – new management strategies
Helmut Salzer (Linz/AT)

16:40 S1-03
Invasive candidiasis in 2024–2026: treatment patterns and outcomes in a multinational real-world cohort
Laman Rahimli (Cologne/DE)

16:50 S1-04
ECMM Candida IV – epidemiology, species distribution, and clinical outcomes in candidemia caused by non-albicans Candida species
Stella Wolfgruber (Graz/AT)

16:00–17:00 Session 2 • Fungal virulence and impact of climate change
Room Lecture hall 5
Chairs Oliver Kurzai (Würzburg/DE), Danila Seidel (Cologne/DE)

16:00 S2-01
From environmental diversity to clinical threat: Does climate change already shape fungal pathogens and virulence?
Grit Walther (Jena/DE)

16:20 S2-02
Heme availability impacts azole susceptibility and ergosterol biosynthesis in *Aspergillus fumigatus*
Ervin M. Alcanzo (Innsbruck/AT)

16:30 S2-03
Antifungal susceptibility and condition-dependent proteomic profiling of *Neocosmospora keratoplastica* from clinical and environmental origins
Ida Ćurtović Pučar (Zagreb/HR)

16:40 S2-04
ARGiS – Azole-Resistant fungi: Gradients in Soils
Alina Nowak-Rainer (Innsbruck/AT)

16:50 S2-05
Macrophage inflammatory responses shape *C. albicans* adaptations to host imposed stresses
Candela Fernández Fernández (Jena/DE)

17:00–18:00 Session 3 • Mycobiome and fungal colonization
Room Aula
Chairs Simon Feys (Leuven/BE), Matthias Egger (Graz/AT)

17:00 S3-01
The role of the Microbiome and Mycobiome in viral associated pulmonary aspergillosis
Simon Feys (Leuven/BE)

17:20 S3-02
Modeling of intravenous caspofungin administration using an intestine-on-chip reveals altered *Candida albicans* microcolonies and pathogenicity
Tim Kaden (Jena/DE)

17:30 S3-03
Unravelling the infection dynamics of *Candida albicans* clinical isolates on gut epithelial cells
Taniya Banerjee (Jena/DE)

17:40 S3-04
Single-cell transcriptomic profiling of the pulmonary landscape during *Candida albicans* colonization and bacterial superinfection
Natalie E. Nieuwenhuizen (Würzburg/DE)

17:50 S3-05
Candidozyma auris in Austria: Evidence for Repeated Importation and Implications for Infection Control
Kathrin Spettel (Vienna/AT)

17:00–18:00 Session 4 • Pediatric fungal infections
Room Lecture hall 5
Chairs Andreas Groll (Münster/DE), Daniela Kohlfürst (Graz/AT)

17:00 S4-01
IFD in pediatric patients with acute leukemia- epidemiology and prophylaxis in Europe and beyond
Konrad Bochennek (Frankfurt am Main/DE)

17:20 S4-02
Mitochondrial intoxication by macrophage-derived reactive oxygen species mediates echinocandin tolerance of intramacrophage *Candida glabrata*
Amir Arastehfar (Würzburg/DE)

17:30 S4-03
Emergence of a High-Risk ST11 Lineage and Early Azole Resistance in Clinical *Candida parapsilosis* Isolates
Roya Vahedi Shahandashti (Innsbruck/AT)

17:40 S4-04
From Bananas to the Clinic: Emerging Clinical Relevance of Fusarium musae within the Fusarium fujikuroi Species Complex
Marta Kozarić (Zagreb/HR)

17:50 S4-05
An Early Decision Point in Alveolar Macrophages Shapes the Outcome of Pulmonary *Aspergillus* Infection
Zahraa Abboud (Würzburg/DE)

18:15–18:45 Keynote Lecture 2
Room Aula
Chair Jürgen Prattes (Graz/AT)

18:15 KL-2
Fungal diseases in HIV positive patients- still an underestimated risk?
Daniele Roberto Giacobbe (Genua/IT)

18:45–19:15 Ehrenmitgliedschaft ÖGMM & Lesungen
Room Aula



19:15–20:15 Poster Session 1
Place Lecture hall 5
see page 28

19:15–21:15 Welcome Reception
see page 40

08:00–08:45 Keynote Lecture 3
Room Aula
Chair Dominic Wichmann (Hamburg/DE)

08:00 KL-3
Influenza associated pulmonary aspergillosis: how it's going, where it's heading
Joost Wauters (Leuven/BE)

08:45–09:45 Industrial Symposium 2
see page 45

10:00–11:00 Session 5 • Novel fungal diagnostics
Room Aula
Chairs Jörg Steinmann (Nuremberg/DE), Kathrin Spettel (Vienna/AT)

10:00 S5-01
New tools for diagnosis and treatment monitoring: from epigenetics to metabolomics
Agostinho Carvalho (Braga/PT)

10:20 S5-02
Unmasking Occult Fungaemia and Fungal Meningitis in Bacteria-Positive Blood Culture Bottles
Isabel Klugherz (Graz/AT)

10:30 S5-03
False-positive galactomannan values in bronchoalveolar lavage fluid are significantly more common in critically ill patients after aspiration
Jürgen Held (Erlangen/DE)

10:40 S5-04
ImmunoPET and LSFM-based Imaging for Early Diagnosis of Invasive Aspergillosis Using Fc-Modified Anti-*Aspergillus fumigatus* Antibodies
Lea Allerchen (Essen/DE)

10:50 S5-05
Blood PCR for Mucorales in Patients with suspected Invasive Mould Infection: Findings from a Single Center
Sarah Sedik (Graz/AT)

10:00–11:00 Session 6 • Host-fungal pathogen interactions
Room Lecture hall 5
Chairs Subhra Biswas (Graz/AT), Cornelia Speth (Innsbruck/AT)

10:00 S6-01
Host defense mechanisms against Mucorales – from A(lbumin) to Z(inc)
Georgios Chamilos (Heraklion/GR)

10:20 S6-02
Galectin-3 regulates macrophage antifungal immunity and host susceptibility to invasive pulmonary aspergillosis
Inês Pereira (Braga, Guimarães/PT)

10:30 S6-03
M-CSF-stimulated alveolar macrophages safeguard from invasive aspergillosis
Andreas Beilhack (Würzburg/DE)

10:40 S6-04
Mitochondrial metabolism tunes „hyphoptosis“ susceptibility in macrophages – A dysfunctional checkpoint in primary immunodeficiencies?
Axel Dietschmann (Jena/DE)

10:50 S6-05
MucorVax: A viral-vector based vaccine to prevent fungal disease
Pramatha Shashidhar (Leuven/BE)

11:15–12:15 Industrial Symposium 3
see page 45

12:30–13:15 Round Table • The Future of Medical Mycology – fungal disease in times of climate change, globalization and emerging resistance
Room Aula

13:15–14:15 Poster Session 2
Place Atelier
see page 31

14:15–15:15 Session 7 • Rethinking risk: Fungal infections in non-classical hosts
Room Aula
Chairs Peter Schellongowski (Vienna/AT), Paul Zajic (Graz/AT)

14:15 S7-01
Pneumocystis in the ICU: An overview
Peter Schellongowski (Vienna/AT)

14:25 S7-02
The role of adjunctive corticosteroids for treatment of severe PJP
Virginie Lemiale (Paris/FR)



14:35 S7-03
Influenza-associated pulmonary aspergillosis: incidence, outcomes and implications for targeted antifungal prophylaxis
Daniel Felber (Graz/AT)

14:45 S7-04
Rare Invasive Fungal Infections in Patients with Hematological Malignancies: Epidemiology, Clinical Course, and Outcomes
Christina Bonk (Munich/DE)

14:55 S7-05
Coccidioidomycosis in Germany: Case series after work-associated travel to Arizona
Volker Rickerts (Berlin/DE)

15:05 S7-06
The Epidemiology of Cryptococcosis in Germany, 2018-2025: A Retrospective Study
Solveig Zöller (Berlin/DE)

14:15–15:15 Session 8 • One Health: Fungicides, Mycotoxins and Resistance
Room Lecture hall 5
Chairs Oliver Kurzai (Würzburg/DE), Joao Brandao (Lissabon/PT)

14:15 S8-01
Fungicide use in Europe –- Implications for Humans
Michaela Lackner (Innsbruck/AT)

14:35 S8-02
Proteomic profiling of virulence and mycotoxin biosynthesis in *Fusarium* species: What is the role of antifungals?
Maja Segvic Klaric (Zagreb/HR)

14:55 S8-03
Fungi and antifungals: an overlooked gap in wastewater surveillance and reuse regulation
Joao Brandao (Lisbon/PT)

15:05 S8-04
Antifungal Tolerance detection in Non-*albicans Candida* Bloodstream Isolates from Innsbruck: An Analysis within the ECMM *Candida* IV Study
Roya Vahedi Shahandashti (Innsbruck/AT)

15:15–16:00 Keynote Lecture 4
Room Aula
Chair Amir Arastehfar (Würzburg/DE)

15:15 KL-4
Candida cell wall architecture: impact on immunity, diagnosis and antifungal susceptibility
Neil Gow (Exeter/GB)

16:00–18:00 DMykG General Assembly
Room Lecture hall 5

18:30-19:30 Guided tour of Graz
see page 40

19:30–23:00 Social evening
see page 40

08:30–10:00 Rapid Fire Session
Room Aula
Chairs Jürgen Löffler (Würzburg/DE), Christina Uitz (Graz/AT)

08:30 RFS-1
RttA – a Novel Regulator of Sterol Homeostasis and Azole Resistance in *Aspergillus fumigatus*
Fabio Gsaller (Innsbruck/AT)

08:40 RFS-2
Rhizopus arrhizus infection rewires host RNA splicing
Michael Richter (Jena/DE)

08:50 RFS-3
ATHANA – Antifungal therapeutic approaches through nanoparticle-based targeting of drugs
Thomas Orasch (Jena/DE)

09:00 RFS-4
Designer Self-Immolative Linkers for Prodruging Antifungals
Ondrej Baszczynski (Prague/CZ)

09:10 RFS-5
Antifungal susceptibility testing of olorofim and manogepix for *Fusarium*, *Scedosporium* and rare fungal pathogens
Enrico Garbe (Jena/DE)

09:20 RFS-6
Grand Escape- How fungi outsmart the human complement system by binding to factor H – A review of 30 years of research
Reinhard Würzner (Innsbruck/AT)

09:30 RFS-7
Targeting TNFR2 to Enhance Innate Immunity Against Pulmonary Aspergillus Infection
Anna M. Arold (Würzburg/DE)

09:40 RFS-8
Proposal and validation of a new Candidozyma auris core genome Multilocus Sequence Typing (cgMLST) scheme
Alexander Aldejohann (Jena/DE)

09:50 RFS-9
Using human airway and alveolar organoid-derived monolayers for quantification of Cryptococcus-host interactions
Sebastian Reusch (Berlin/DE)

10:15–11:15 Session 9 • Precision antifungal therapy: translating pharmacology into better patient outcomes (ÖGIT/ÖGMM)
Room Aula
Chairs Robert Krause (Graz/AT), Cornelia Lass-Flörl (Innsbruck/AT)

10:15 S9-01
MICs as tool for treatment stratification?
Cornelia Lass-Flörl (Innsbruck/AT)

10:35 S9-02
Pharmacokinetic considerations of antifungals in special populations
Roger Brüggemann (Nijmegen/NL)

10:55 S9-03
Optimized antifungal dosing in critically ill patients
Robert Krause (Graz/AT)

10:15–11:15 Session 10 • Systems biology of fungal infections
Room Lecture hall 5
Chairs Agostinho Carvalho (Braga/PT), Ulrike Binder (Innsbruck/AT)

10:15 S10-01
Bioluminescence imaging to study fungal biology and pathogenesis
Matthias Brock (Nottingham/GB)

10:35 S10-02
Exploring the role of extracellular vesicles in fungal immunity in human macrophages
Lars Schnell (Lübeck/DE)

10:45 S10-03
Cholesterol metabolism regulates phagosome biogenesis and maturation during *Aspergillus fumigatus* infection
Adriana Teixeira Costa (Braga/PT)

10:55 S10-04
Human Organ-on-Chip Platforms for Assessing Efficacy and Toxicity of Nanoparticle Antifungal Therapies
Tim Kaden (Jena/DE)

11:05 S10-05
Itaconate impairs macrophage effector functions and increases susceptibility to invasive pulmonary aspergillosis
Tatiana Fernandes (Braga/PT)

11:30–12:30 Session 11 • Mucosal fungal interactions
Room Aula
Chairs Mark S. Gresnigt, Ilse Jacobsen (Jena/DE)

11:30 S11-01
Mucosal Candidiasis: From tolerance, fungal pathogenicity and inflammation to therapeutic management
Ilse Jacobsen (Jena/DE)

11:50 S11-02
An organ-on-chip model to study vulvovaginal candidiasis and the interplay between fungal pathogenicity and inflammation
Kar On Cheng (Jena/DE)

12:00 S11-03
Spatial Analysis of *Candida albicans* and *Candida auris* in Co-Cultivation on Human Intestinal Organoid-Derived Monolayers
Alexandra Löwe (Berlin/DE)

12:10 S11-04
Cross-kingdom interaction between *Candida albicans* and *Akkermansia muciniphila* in an enterocyte infection model
Rusudan Goliadze (Jena/DE)

12:20 S11-05
Elucidating alternative virulence strategies in *Candida albicans* clinical isolates
Myrto Katsipoulaki (Jena/DE)

11:30–12:30 Session 12 • Dermatomykologie
Room Lecture hall 5
Chairs Pietro Nenoff, Silke Uhrlaß (Rötha/DE)

11:30 S12-01
Tinea capitis im Verlauf der Zeit
Gabriele Ginter-Hanselmayer (Graz/AT)

11:50 S12-02
Onychomykose – a diagnostic and therapeutic challenge
Christin Pelzer (St. Gallen/CH)

12:10 S12-03
Comparison of PCR tests for the detection of dermatophytes in onychomycosis
Silke Uhrlaß (Rötha/DE)

12:20 S12-04
Trichophyton indotineae auf dem Vormarsch? Resistenzsituation und epidemiologische Daten aus Österreich
Marjan Motamedi (Vienna/AT)

12:30–13:00 Closing
Room Aula

schülke

schülke hat, was Hände lieben.



wertvolle Hautpflege

pflegende Hände-desinfektion

sanfte Hautreinigung

verlässlicher Hautschutz

Weil Hände Heldinnen sind, verdienen sie das Beste:

Verlässlichen Schutz und wertvolle Pflege – perfekt abgestimmt für den Dauereinsatz im Dienst der Gesundheit.

Nachhaltig sicher. Für heute. Für morgen. Für alle.

we protect lives worldwide

www.schuelke.at



© Miroslav Posavec- stock.adobe.com

19:15–20:15 Poster Session 1
Place Lecture hall 5
Moderator Helmut Salzer (Linz/AT), Matthias Egger (Graz/AT)

19:15 PP-1-01
Posaconazole-induced Excess Mineralocorticoid Syndrome – Observations in Three Pediatric Patients
Andreas Groll (Münster/DE)

19:18 PP-1-02
Invasive Aspergillosis in ICU patients with Influenza during the 2025/26 season: a multicenter study in Austria
Sarah Sedik (Graz/AT)

19:21 PP-1-03
Life-threatening Invasive Fungal Infections in Patients With T-Cell Large Granular Lymphocytic Leukemia
Jannik Stemler (Cologne/DE)

19:24 PP-1-04
Implementation of an international weekly expert case conference for invasive fungal diseases – an initiative of the ECMM Excellence Center Cologne
Sara Sander (Cologne/DE)

19:27 PP-1-05
Bioassay zur Olorofim-Bestimmung im Serum: eine Alternative im Vergleich zu LC-MS/MS?
Hedda Luise Verhasselt (Essen/DE)

19:30 PP-1-06
Fluconazol-Bestimmung aus Speichel unter Anwendung von Volumetric Absorptive Microsampling (VAMS) und isokratischer HPLC-UV – Projekt der PharMSchool Münster
Franziska Zimbelmann (Münster/DE)

19:33 PP-1-07
Cardiac and ophthalmic involvement in candidaemia: results from the ECMM Candida III study
Daniel Felber (Graz/AT)

19:36 PP-1-08
Petromyces alliaceus – Erstmals als Erreger einer Onychomykose nachgewiesen
Jochen Brasch (Kiel/DE)

19:39 PP-1-09
Itraconazole-resistant *Trichophyton rubrum* isolates showed transcriptional up regulation of sterol 14-α demethylase genes *Erg11A* and *Erg11B* compared to sensitive wild type strains
Cornelia Wiegand (Jena/DE)

19:42 PP-1-10
An overview of the pathogen spectrum in 2025 in molecular dermatophyte diagnostics in private dermatology practices
Silke Uhrlaß (Rötha/DE)

19:45 PP-1-11
Pilot evaluation of the EurobioPlex two-step PCR strategy for dermatophyte diagnostics
Maximilian Köster (Basel/CH)

19:48 PP-1-12
Prävalenz von Dermatophyten bei Haustieren: Auswertung der kulturellen Diagnostik von Hautpilzen in einem veterinärmedizinischen Diagnostiklabor in 2025
Marianne Schneider (Bad Kissingen/DE)

19:51 PP-1-13
Performance of a Candida Mannan Antigen lateral flow assay in Diagnosing Candidemia and Invasive Candidiasis
Sarah Sedik (Graz/AT)

19:54 PP-1-14
Candi-MAG study: Evaluation of a *Candida* Mannan Antigen Lateral Flow Assay for the Diagnosis of Candidemia
Stephan Steixner (Innsbruck/AT)

19:57 PP-1-16
Fosmanogepix expanded access in patients with invasive mould infections from Germany, Austria and Switzerland
Jannik Stemler (Cologne/DE)

20:00 PP-1-17
Development of a complex in vitro cell culture system for investigating antifungal drug delivery approaches
Derya Nur Cömert (Jena/DE)

20:03 PP-1-18
MedicalGuideline.org – a Collaborative Web-Based Platform for Structured Clinical Guideline Development – Concept, Implementation and Application
Nico Bekaan (Cologne/DE)

20:06 PP-1-19
Association between 1,3-Beta-D-Glucan and immune dysregulation in liver cirrhosis
Matthias Egger (Graz/AT)

20:09 PP-1-20
Population pharmacokinetic of fluconazole in paediatric patients with allogeneic haematopoietic cell transplantation
Franziska Zimbelmann (Münster/DE)

13:15–14:15 Poster Session 2
Place Atelier
Moderator Mark S. Gresnigt (Jena/DE), Ulrike Binder (Innsbruck/AT)

Poster Session 2-I

13:15 PP-2-01
In-vitro-Empfindlichkeitstestung von Candida-Spezies gegenüber klinisch relevanten Antimykotika bei Vulvovaginalkandidose
Werner Mendling (Wuppertal/DE)

13:19 PP-2-02
Environmental Detection of Clade III *Candidozyma auris* in the Absence of Clinical Isolates
Angelika Bauer (Innsbruck/AT)

13:23 PP-2-03
Co-treatment of sertraline with amphotericin B or amorolfine change inhibitory concentration levels of antifungals and up regulates expression of MDR3 transporter in several *Trichophyton indotineae* isolates
Anke Burmester (Jena/DE)

13:27 PP-2-04
Activity of echinocandins including rezafungin against Candida auris biofilms
Jörg Steinmann (Essen/DE)

13:31 PP-2-05
Exploring Efflux Pump–Mediated Azole Resistance in *Aspergillus fumigatus*
Chendo Dieleman (Innsbruck/AT)

13:35 PP-2-06
N-chlorotaurine limits the pro-inflammatory reaction of granulocytes and alveolar macrophages in response to *Aspergillus fumigatus*
Cornelia Speth (Innsbruck/AT)

13:39 PP-2-07
Antifungal Activity of Octenidine against Emerging Candida Species In Vitro
Madita Loy (Vienna/AT)

13:43 PP-2-08
PDR1 Gain-of-Function Mutations Drive Multidrug Efflux Pump Overexpression in Azole-Resistant Nakaseomyces glabratus: A Comparative Analysis of Targeted RNA Sequencing and RT-qPCR
Richard Kriz (Vienna/AT)

13:47 PP-2-09
Genomic analysis of longitudinal *Coccidioides posadasii* isolates from relapsing disseminated coccidioidomycosis
Mandy Messal (Berlin/DE)

13:51 PP-2-10
Epidemiology of opportunistic and transmissible Candida species in Mwanza, Tanzania
Johannes Zitzmann, Alexander Aldejohann (Würzburg/DE)

13:55 PP-2-11
Azole resistance of *Aspergillus fumigatus* in Germany and its molecular detection
Josephine Schötz (Jena/DE)

13:59 PP-2-12
In Vitro Polyhexanide Exposure Induces Azole Resistance in Nakaseomyces glabratus via PMA1 Mutations
Thomas Ellinger (Vienna/AT)

Poster Session 2-II

13:15 PP-2-14
IL-22 induced by *C. albicans* reduces the severity of invasive *S. aureus* pneumonia in mice
Tobias Köhler (Würzburg/DE)

13:19 PP-2-15
Decoding CXCL10: A potential regulator of macrophage responses to pulmonary infections
Jeany Söhnlein (Würzburg/DE)

13:23 PP-2-16
Comparative Analysis of Macrophage Interactions with *Candida glabrata* and *Candida auris*
Janik Adriana Tomás Morales (Jena/DE)

13:27 PP-2-17
Monocyte-Mediated Immune Responses to Co-Infections with *Candida albicans* and *Staphylococcus aureus*
Gabriel Braune (Würzburg/DE)

13:31 PP-2-18
The commensal functions of the fungal peptide toxin candidalysin
Tim Bastian Schille (Jena/DE)

13:35 PP-2-19
Role of Chitin Binding Proteins in Immune Regulation of Human Keratinocytes Responding to Fungal Infection
Carlotta Imelmann (Hamburg/DE)

13:39 PP-2-20
Dual effect of 5-Fluorouracil against Pancreatic Ductal Adenocarcinoma (PDAC) and against the tumor-promoting fungus *Malassezia globosa*
Günter Rambach (Innsbruck/AT)


13:43 PP-2-21
Host Adaptation by Reduced Biofilm Formation Drives Outbreak Persistence of a Major High Priority Human Fungal Pathogen
Farnaz Daneshnia (Amsterdam/NL)

13:47 PP-2-22
Interaction of *Malassezia* with pancreatic enzymes in pancreatic cancer: potential role in fungal persistence and inflammatory activation
Dina Aly, Cornelia Speth (Innsbruck/AT)

13:51 PP-2-24
Repurposing a Human Cytochrome P450 Activity Assay for High-Throughput Screening of Fungal CYP51 Inhibitors
Tendral Sekar (Innsbruck/AT)

GILEAD

Veklury® remdesivir
VON ANFANG AN ENTSCHEIDEND



COVID-19 frühzeitig therapieren, Risiken minimieren

Schnell wieder im Leben[1]

VEKLURY® – antivirale Therapieoption bei hospitalisierten COVID-19-Patient:innen

1. Beigel JH et al. N Engl J Med. 2020; 383: 1813–1826

Veklury 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Pharmakotherapeutische Gruppe: Antivirale Mittel zur systemischen Anwendung, direkt wirkende antivirale Mittel, andere antivirale Mittel, ATC-Code: J05AB16 **Qualitative und quantitative Zusammensetzung:** Jede Durchstechflasche enthält 100 mg Remdesivir. Nach der Rekonstitution enthält jede Durchstechflasche 5 mg/ml Remdesivir-Lösung. **Sonstige Bestandteile:** *Sonstige Bestandteile mit bekannter Wirkung:* Jede Durchstechflasche enthält 3 g Hexakis- und Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose-Natriumsalz (1:6,2-6,9). Salzsäure (zur Einstellung des pH-Wertes) (E507), Natriumhydroxid (zur Einstellung des pH-Wertes) (E524). **Anwendungsgebiete:** Veklury wird angewendet zur Behandlung der Coronavirus-Krankheit 2019 (COVID-19) bei Erwachsenen und pädiatrischen Patienten (im Alter von mindestens 4 Wochen und mit einem Körpergewicht von mindestens 3 kg): • mit einer Pneumonie, die eine zusätzliche Sauerstoffzufuhr erfordert (Low- oder High-Flow Sauerstofftherapie oder eine andere nicht-invasive Beatmung zu Therapiebeginn) • die keine zusätzliche Sauerstoffzufuhr benötigen und ein erhöhtes Risiko haben, einen schweren COVID-19-Verlauf zu entwickeln. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. **Inhaber der Zulassung:** Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Irland **Rezept- und apothekenpflichtig, NR**.
Weitere Angaben zu Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen, Schwangerschaft und Stillzeit, sowie Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation.
AT-VKY-0105

Gilead Sciences GesmbH
Wagramer Straße 19, 1220 Wien
AT-VKY-0110; Erstellungsdatum: 03/2026

GENERAL INFORMATION



© Lance Bellers- stock.adobe.com

Registration

Please register online at www.dmykg-kongress.de. There you will find all information on conference fees, payment of fees and payment confirmations as well as the General Terms and Conditions.

Conference language

The conference language is English.

Name badges

Access to the conference and the industrial exhibition is only possible with a name badge. You will receive this at the check-in desk.

Certification

The MYK 2026 is recognised by the **Austrian Medical Association** as follows:
21 DFP-Points

The MYK 2026 is approved by the **Academy for Advanced Veterinary Training** as follows:
17 September – 4 hours
18 September – 5 hours
19 September – 4 hours

Publication of abstracts

The abstract book for the conference will be published online on the conference homepage at www.dmykg-kongress.de.

Photo competition

There will again be a photo competition at MYK 2026 with photos submitted by participants. All information and the opportunity to submit photos can be found on the conference website www.dmykg-kongress.de.

Catering

During breaks, a small selection of fruit and snacks as well as coffee and tea will be available. Lunch can be purchased at your own expense in the cafeteria. Water stations are available at the venue. For environmental reasons, please bring refillable water bottles with you.



Poster sessions

Please note: Posters may be displayed throughout the entire conference.

Posters for Poster session 1 will be located in Lecture hall 5, and posters for Poster session 2 will be located in the Atelier.

Please take down your posters yourself by 11:30 on 19 September at the latest. Posters will neither be stored nor forwarded.

Please produce your poster in A0 format (84.1 cm x 118.9 cm, portrait format). Fixing material is provided on the poster wall, which will be labelled with your poster number. The poster prizes will be awarded at the social evening.



Speaking times for talks

Please prepare your talk in such a way that the allocated time, which includes the discussion, is maintained. The chairs are required to ensure that the speaking time is adhered to.



Technical information

Please prepare your presentation in aspect ratio 16:9. PDF and PowerPoint are accepted. The use of different versions during the submission of presentations could lead to formatting issues. Please note that the corresponding CODEC for the play-back of video sequences must be provided by yourself. Corresponding technical equipment will be provided on site.

There will be no central media check-in. Presentations will be received directly in the respective lecture hall. Please bring your presentation file to the congress on a mobile storage medium, ideally on a USB drive. The use of your own computer for your presentation is not necessary and not intended.



Prizes of the Foundation of the German speaking Mycological Society e. V.

Publication Prize of the DMykG Foundation

The DMykG e. V. Foundation awards prizes for excellent scientific publications in the fields of medical and veterinary mycology. The prizes are funded with EUR 1,000 each.

These prizes will be awarded during the award ceremony.

Poster prizes of the DMykG Foundation

The foundation awards three poster prizes for excellent scientific work, which can cover the whole spectrum of DMykG research work. In addition, the Hans Rieth Poster Prize is awarded for the special didactic design of a scientifically excellent poster. The poster prizes are worth EUR 250 each.

These prizes will be awarded during the social evening.

Prizes of the German speaking Mycological Society e. V.

Research Award

The DMykG awards the Research Promotion Prize (funding: EUR 5,000) to members who have made excellent, internationally recognised achievements in the areas of clinical or experimental research in the field of medical mycology. The award winner should be expected to make significant scientific achievements in his/her future career.

The research award will be awarded during the award ceremony.

Schönlein Plaque

The Johann-Lucas-Schönlein-Plaque, donated by the DMykG e. V., is awarded to natural persons who have rendered outstanding services to the cause of mycology in the spirit of the society. The plaque is awarded during the social evening.

Photo competition


The three best photos in the competition will be selected by the participants. The awards ceremony (the first prize is endowed with EUR 500, the second and third prizes with EUR 250 each) will take place during the social evening.

Prizes of the Austrian Society for Medical Mycology

Publication Prize of the ÖGMM

The Austrian Society for Medical Mycology (ÖGMM) annually awards a Publication Prize for the best scientific publication in the field of medical mycology authored by an ÖGMM member. The prize is awarded on an alternating annual basis for outstanding publications in “Basic Mycological Research” and “Clinical and Applied Mycological Research”. The ÖGMM Publication Prize is endowed with EUR 1,000.

Med Uni Graz
Medizinische Universität Graz
Neue Stiftingtalstraße 6
8010 Graz



SOCIAL PROGRAMME

Welcome Reception

Come together over drinks and snacks and enjoy the first evening of the congress in a very pleasant atmosphere. Get in the mood for MYK 2026 at the welcome reception in the industrial exhibition. Have interesting conversations with colleagues, old friends and meet new acquaintances.



© Rawpixel.com I 395377318 I shutterstock.com

Date	Thursday, 17 September
Time	19:15–21:15
Place	Foyer / Industrial exhibition
Costs	free of charge for congress participants (registration is requested) Accompanying persons EUR 10

Social evening

Celebrate the end of the second day of the congress at the Landhauskeller in Graz, review what you have experienced so far and enjoy an entertaining evening with good food and interesting discussions.



© Lucija Novak

Date	Friday, 18 September
Time	19:30–23:00
Place	Landhauskeller Graz Schmiedgasse 9 | 8010 Graz
Costs	EUR 75 Participants / accompanying persons EUR 50 Students

Guided tour of Graz

Enjoy the best that Graz has to offer! Look forward to interesting stories, fascinating insights, and the unique charm of Graz—an ideal opportunity to combine your conference visit with a special city experience.



© Rostislav Ageev- stock.adobe.com

Date	Friday, 18 September
Time	18:30-19:30
Place	Town hall

© Lisa Payr - stock.adobe.com



© Vladislav Gajic - stock.adobe.com

We would like to sincerely thank the following companies for their kind support:

Sponsors

Mundipharma Gesellschaft m.b.H

Basilea Pharmaceutica International Ltd, Allschwil

Shionogi GmbH

Further supporting companies

Gilead Sciences GesmbH

Schülke & Mayr GmbH

Exhibitors

Associates of Cape Cod Int'l, Inc
Biomedica Medizinprodukte GmbH
Dynamic42 GmbH
FUJIFILM Wako Chemicals Europe GmbH
PathoNostics B.V.
TECOmedical GmbH

Disclosure

In accordance with the guidelines of the FSA Code, the support services provided by members of the Voluntary Self-Regulation of Pharmaceutical Companies (FSA) are disclosed, including on the official conference website www.dmykg-kongress.de.

Associates of Cape Cod Int'l, Inc: 1.580 EUR; Basilea Pharmaceutica International Ltd, Allschwil: 12.500 EUR; Biomedica Medizinprodukte GmbH: 1.400 EUR; Dynamic42 GmbH: 3.150 EUR; FUJIFILM Wako Chemicals Europe GmbH: 2.100 EUR; Gilead Sciences GesmbH: 2.200 EUR; Mundipharma Gesellschaft m.b.H: 15.000 EUR; PathoNostics B.V.: 3.150 EUR; Schülke & Mayr GmbH: 1.100 EUR; Shionogi GmbH: 12.500 EUR; TECOmedical GmbH: 2.100 EUR

State at printing

We would like to thank the following sponsors for their support:

Region Graz

Stadt Graz

MEDIA COOPERATIONS

We would like to thank the following media partners for their support:

Trillium Diagnostik
Zeitschrift für interdisziplinäre Medizin

Journal of Fungi
Zeitschrift für Mykologie



14:45–15:45 Industrial Symposium 1
Mundipharma Gesellschaft m.b.H
Protecting the vulnerable host: Clinical settings for antifungal prophylaxis

Room Aula
Chair Robert Krause (Graz/AT)

14:45 Welcome note, introduction and overview
Robert Krause (Graz/AT)

14:55 Hemato-Oncology Focus
Jannik Stemler (Cologne/DE)

15:10 ICU Focus
Lisa Kriegl (Graz/AT)



15:25 Discussion

08:45–09:45 Industrial Symposium 2
Basilea Pharmaceutica International Ltd, Allschwil
Current challenges in fungal infections: role of Fosmanogepix

Room Aula
Chair Cornelia Lass-Flörl (Innsbruck/AT)

08:45 Current unmet medical need in IMI
Martin Hönigl (Graz/AT)

08:57 Unmet medical need in IC
Jürgen Prattes (Graz/AT)

09:09 Fosmanogepix and EAP experience
Jannik Stemler (Cologne/DE)

09:29 Panel discussion

11:15–12:15 Industrial Symposium 3
Shionogi GmbH
Invasive Pilzinfektionen im Wandel: Diagnostik und Therapie neu denken

Room Aula
Chair Martin Hönigl (Graz/AT)


11:15 Begrüßung und Intro
Martin Hönigl (Graz/AT)

11:20 Relevanz von Pilzinfektionen – Diagnostik als Schlüssel zur Therapieentscheidung
Michaela Lackner (Innsbruck/AT)

11:35 Häufige Pilze auf der Intensivstation jenseits von Schimmelpilzen
Tobias Lahmer (Munich/DE)

11:50 Invasive Schimmelpilz-Infektionen: Wie sieht die Zukunft aus?
Oliver Cornely (Cologne/DE)

12:05 Abschlussdiskussion und Abschied



Booth number	Exhibitor
1	FUJIFILM Wako Chemicals Europe GmbH
3	Shionogi GmbH
4	PathoNostics B.V.
5	Mundipharma Gesellschaft m.b.H
6	Dynamic42 GmbH
7	Biomedica Medizinprodukte GmbH
8	TECOmedical GmbH
9	Associates of Cape Cod Int'l, Inc

State at printing

INDEX SPEAKERS, AUTHORS AND CHAIRS



© Wolfgang Gibura - stock.adobe.com

A
Abboud, Z. 17
Alcanzo, E. M. 15
Aldejohann, A. 22, 32
Allerchen, L. 18
Aly, D. 33
Arastehfar, A. 16, 21
Arold, A. M. 22

B
Banerjee, T. 16
Baszczynski, O. 22
Bauer, A. 31
Beilhack, A. 19
Bekaan, N. 30
Binder, U. 23, 31
Biswas, S. 19
Bochennek, K. 12, 16
Bonk, C. 20
Brandao, J. 20, 21
Brasch, J. 29
Braune, G. 33
Brock, M. 12, 23
Brüggemann, R. 12, 23
Burmester, A. 31

C
Carvalho, A. 12, 18, 23
Chamilos, G. 12, 19
Cheng, K. O. 24
Cömert, D. N. 30
Cornely, O. A. 12, 14, 45
Ćurtović Pučar, I. 15

D
Daneshnia, F. 33
Dieleman, C. 31
Dietschmann, A. 19

E
Egger, M. 15, 28, 30
Ellinger, T. 32

F
Felber, D. 20, 28
Fernandes, T. 24
Fernández Fernández, C. 15
Feys, S. 15

G
Garbe, E. 22
Giacobbe, D. R. 12, 17
Ginter-Hanselmayer, G. 12, 25
Goliadze, R. 24
Gow, N. 12, 21
Gresnigt, M. S. 24, 31
Groll, A. 16, 28
Gsaller, F. 22

H
Held, J. 18
Hönigl, M. 8, 14, 45

I
Imelmann, C. 33

J
Jacobsen, I. 12, 24

K
Kaden, T. 16, 24
Katsipoulaki, M. 24
Klaric, M. S. 12, 21
Klugherz, I. 18
Köhler, T. 32
Kohlfürst, D. 16
Köster, M. 29
Kozarić, M. 16
Krause, R. 12, 14, 23, 44
Kriegl, L. 44
Kriz, R. 32
Kurzai, O. 10, 15, 20

L
Lackner, M. 10, 12, 20, 45
Lahmer, T. 45
Lass-Flörl, C. 12, 23, 45
Lemiale, V. 12, 20
Löffler, J. 22
Löwe, A. 24
Loy, M. 31

M
Mendling, W. 31
Messal, M. 32
Motamedi, M. 25

N
Nenoff, P. 25
Nieuwenhuizen, N. E. 16
Nowak-Rainer, A. 15

O
Orasch, T. 22

P
Pelzer, C. 12, 25
Pereira, I. 19
Prattes, J. 8, 17, 45

R
Rahimli, L. 14
Rambach, G. 33
Reusch, S. 23
Richter, M. 22
Rickerts, V. 20

S
Salzer, H. 12, 14, 28
Sander, S. 28
Schellongowski, P. 12, 20
Schille, T. B. 33
Schneider, M. 29
Schnell, L. 23
Schötz, J. 32
Sedik, S. 18, 28, 29
Seidel, D. 15
Sekar, T. 33
Shashidhar, P. 19
Söhnlein, J. 32
Speth, C. 19, 31, 33
Spettel, K. 16, 18
Sprute, R. 14
Steinmann, J. 18, 31
Steixner, S. 29
Stemler, J. 28, 29, 44, 45

T
Teixeira Costa, A. 23
Tomás Morales, J. A. 32

U
Uhrlaß, S. 25, 29
Uitz, C. 22

V
Vahedi Shahandashti, R. 16, 21
van de Veerdonk, F. 12, 14
Verhasselt, H. L. 28

W
Walther, G. 12, 15
Wauters, J. 12, 18
Wichmann, D. 18
Wiegand, C. 29
Wolfgruber, S. 15
Würzner, R. 22

Z
Zajic, P. 20
Zimbelmann, F. 28, 30
Zitzmann, J. 32
Zöller, S. 20


© Photofex- stock.adobe.com

basilea



We are committed to developing innovative antibacterials and antifungals to treat patients with severe and life-threatening infections

basilea.com



▼REZZAYO®
rezafungin acetate

Das Echinocandin der nächsten Generation für Ihre Patienten mit invasiver Candidiasis

Mit einem differenziertem PK/PD-Profil für eine schnelle fungizide Aktivität.[1–3]

- **Schnelles** Anfluten[2,3]
- **Tiefe** Gewebegängigkeit im präklinischen Modell[4,a]
- **Breites** Candida-Wirkspektrum[5]
- **Einfaches** Therapiemanagement[1]
- **1 x** wöchentliche Gabe[1]

REZZAYO® **ist für die Behandlung von invasiven Candida-Infektionen bei Erwachsenen indiziert.[1]**

a Im präklinischem Rattenmodell untersucht.

1. Fachinformation ***REZZAYO®*** (Rezafungin), Stand 06/2026. | **2.** Thompson GR III et al. Lancet 2023; 401(10370):49–59. | **3.** Sandison T et al. Antimicrob Agents Chemother 2017; 61(2):e01627–16. | **4.** Ong V et al. Antimicrob Agents Chemother 2017;61:e01626–16. **5.** Thompson GR III et al. Lancet Infect Dis 2024; 24(3):319–328.

REZZAYO 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

Wirkstoff: Rezafungin (als Acetat) Verschreibungspflichtig.

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden.

Zusammensetzung: *Arzneilich wirksamer Bestandteil:* Jede Durchstechflasche enthält 200 mg Rezafungin (als Acetat). *Sonstige Bestandteile:* Mannitol, Histidin, Polysorbat 80, Salzsäure (zur pH-Wert-Einstellung), Natriumhydroxid (zur pH-Wert-Einstellung). **Anwendungsgebiete:** REZZAYO wird angewendet zur Behandlung der invasiven Candidainfektion bei Erwachsenen. Es sind die offiziellen Richtlinien zur sachgemäßen Anwendung von Antimykotika zu beachten. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile, Überempfindlichkeit gegen andere Arzneimittel der Klasse der Echinocandine. **Nebenwirkungen:** Sehr häufig: Anämie: Hypokaliämie; Diarrhoe; Fieber. Häufig: Hypomagnesiämie, Hypophosphatämie; Hypotonie; Giemen; Erbrechen, Übelkeit, Abdominalschmerz, Obstipation; Erythem, Ausschlag; erhöhte alkalische Phosphatase im Blut, erhöhte Leberenzyme, erhöhte Alaninaminotransferase, erhöhte Aspartataminotransferase, erhöhtes Bilirubin im Blut; Infusionsbedingte Reaktionen (wie Rötung, Gefühl der Wärme, Übelkeit und Brustenge). Gelegentlich: Hyperphosphatämie, Hyponatriämie; Phototoxizität; Tremor; erhöhte Eosinophilenzahl. Nicht bekannt: Anaphylaktische Reaktion, Urtikaria. **Warnhinweis:** Arzneimittel für Kinder unzugänglich aufbewahren. **Mundipharma GmbH, 60549 Frankfurt am Main** **06-26**

Meldung unerwünschter Ereignisse: Nebenwirkungen/unerwünschte Ereignisse können direkt an das Bundesamt für Sicherheit im Gesundheitswesen (BASG) unter www.basg.gv.at oder als E-Mail an Mundipharma drugsafety@mundipharma.at gemeldet werden.

mundipharma

Mundipharma Gesellschaft m. b. H.
Wiedner Gürtel 13 – Turm 24 – OG 15
A-1100 Wien
Tel: +43 (0)1 523 25 05
Email: office@mundipharma.at

Werbematerial von Mundipharma. Nur für medizinisches Fachpersonal.
®: ***REZZAYO*** ist ein eingetragenes Warenzeichen der Napp Pharmaceutical Group Limited, einem Unternehmen des Mundipharma-Netzwerks.
AT-RZF-2600011 Juli 2026